Inhibition of bone resorption by bisphosphonates: Interactions between bisphosphonates, osteoclasts, and bone

[1]  P. Daley-Yates,et al.  A comparison of the pharmacokinetics of 14C-labelled APD and 99mTc-labelled APD in the mouse , 1988, Calcified Tissue International.

[2]  C. Bergot,et al.  Different schedules of administration of (3 amino-1-hydroxypropylidene)-1, 1 bisphosphonate induce different changes in pig bone remodeling , 1987, Calcified Tissue International.

[3]  P. Marie,et al.  Inhibition by aminohydroxypropylidene bisphosphonate (AHPrBP) of 1,25(OH)2 vitamin D3-induced stimulated bone turnover in the mouse , 1985, Calcified Tissue International.

[4]  E. Hausmann,et al.  The alteration of osteoclast morphology by diphosphonates in bone organ culture , 1976, Calcified Tissue Research.

[5]  H. Fleisch,et al.  The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals , 1973, Calcified Tissue Research.

[6]  H. Fleisch,et al.  Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl2MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats , 1973, Calcified Tissue Research.

[7]  H. Shinoda,et al.  Structure-activity relationships of various bisphosphonates , 2006, Calcified Tissue International.

[8]  H. Fleisch,et al.  Effect of diphosphonates on glycogen content of rabbit ear cartilage cells in culture , 2006, Calcified Tissue International.

[9]  P. Reitsma,et al.  Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) in rats , 2006, Calcified Tissue International.

[10]  W. Jee,et al.  The comparative effects of dichloromethylene diphosphonate (Cl2MDP) and ethane-1-hydroxy-1,1-diphosphonate (EHDP) on growth and modeling of the rat tibia , 1977, Calcified Tissue Research.

[11]  S. Ogata,et al.  Prevention of bone loss by bisphosphonate YM175 in ovariectomized dogs with dietary calcium restriction. , 1996, Japanese journal of pharmacology.

[12]  P. Schlesinger,et al.  Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. , 1990, The Journal of clinical investigation.

[13]  J. Reginster,et al.  PREVENTION OF POSTMENOPAUSAL BONE LOSS BY TILUDRONATE , 1989, The Lancet.

[14]  J. Sculier,et al.  Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor‐associated hypercalcemia: A randomized comparison between a 3‐day treatment and single 24‐hour infusions , 1989, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[15]  S. Ralston,et al.  COMPARISON OF THREE INTRAVENOUS BISPHOSPHONATES IN CANCER-ASSOCIATED HYPERCALCAEMIA , 1989, The Lancet.

[16]  J. Tobias,et al.  Glucocorticoids impair bone resorptive activity and viability of osteoclasts disaggregated from neonatal rat long bones. , 1989, Endocrinology.

[17]  Gowen,et al.  Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. , 1989, The Journal of clinical investigation.

[18]  T. Chambers,et al.  Dichloromethylenebisphosphonate (Cl2MBP) inhibits bone resorption through injury to osteoclasts that resorb Cl2MBP-coated bone. , 1989, Bone and mineral.

[19]  G. Hattersley,et al.  Generation of osteoclastic function in mouse bone marrow cultures: multinuclearity and tartrate-resistant acid phosphatase are unreliable markers for osteoclastic differentiation. , 1989, Endocrinology.

[20]  I. Reid,et al.  Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) , 1988 .

[21]  G. van der Pluijm,et al.  Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: The effect of a bisphosphonate , 1988, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[22]  J. Mönkkönen,et al.  Distribution of [14C]clodronate (dichloromethylene bisphosphonate) disodium in mice. , 1987, Toxicology and applied pharmacology.

[23]  D. Thiebaud,et al.  Paget's disease of bone treated in five days with AHPrBP (APD) per Os , 1987, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[24]  P. McSheehy,et al.  Osteoblastic cells mediate osteoclastic responsiveness to parathyroid hormone. , 1986, Endocrinology.

[25]  Bijvoet Ol,et al.  Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. , 1986 .

[26]  S. Ralston,et al.  COMPARISON OF AMINOHYDROXYPROPYLIDENE DIPHOSPHONATE, MITHRAMYCIN, AND CORTICOSTEROIDSICALCITONIN IN TREATMENT OF CANCER-ASSOCIATED HYPERCALCAEMIA , 1985, The Lancet.

[27]  B. Thomson,et al.  Effect of substrate composition on bone resorption by rabbit osteoclasts. , 1984, Journal of cell science.

[28]  H. Sleeboom,et al.  COMPARISON OF INTRAVENOUS (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE AND VOLUME REPLETION IN TUMOUR-INDUCED HYPERCALCAEMIA , 1983, The Lancet.

[29]  H. Fleisch.  Bisphosphonates : Mechanisms of Action and Clinical Applications , 1983 .

[30]  R. Talbert,et al.  Clodronate kinetics and bioavailability , 1982, Clinical pharmacology and therapeutics.

[31]  T. Chambers,et al.  Calcitonin alters behaviour of isolated osteoclasts , 1982, The Journal of pathology.

[32]  H. Fleisch,et al.  The effects of 1-hydroxyethane-1,1-diphosphonate and dichloromethanediphosphonate on collagen synthesis by rabbit articular chondrocytes and rat bone cells. , 1981, The Biochemical journal.

[33]  F. Preston,et al.  EFFECT OF DICHLOROMETHYLENE DIPHOSPHONATE IN PAGET'S DISEASE OF BONE AND IN HYPERCALCÆMIA DUE TO PRIMARY HYPERPARATHYROIDISM OR MALIGNANT DISEASE , 1980, The Lancet.

[34]  L.,et al.  TREATMENT OF PAGET'S DISEASE WITH (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE (A.P.D.) , 1979, The Lancet.

[35]  H. Fleisch,et al.  The effect of several diphosphonates on acid phosphohydrolases and other lysosomal enzymes. , 1976, Biochimica et biophysica acta.

[36]  D. Fink,et al.  SCREENING FOR BREAST CANCER , 1976, The Lancet.

[37]  Russell Rgg..  Diphosphonates and polyphosphates in medicine , 1975 .

[38]  R. Altman,et al.  Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans). , 1973, The New England journal of medicine.

[39]  H. Fleisch,et al.  Effect of Pyrophosphate on Dissolution of Hydroxyapatite and Its Possible Importance in Calcium Homeostasis.∗ , 1966, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.